ArticleViruses2025
Predictive Factors for HBsAg Seroconversion Following Acute Hepatitis B Virus Infection: A Multicenter BUHASDER Study.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experience with the effect of antiviral therapy on HBsAg seroconversion in acute hepatitis B is limited. We aimed to evaluate the factors affecting HBsAg seroconversion in patients with acute hepatitis B (AHB) receiving antiviral treatment. We performed a retrospective and multicenter study involving 107 adult patients who received antiviral treatment for AHB between January 2018 and December 2023. The median age was 48 (min-max, 18-91) years, and 66.3% of the patients were male; 70 patients with 24-week follow-up (15 patients without HBsAg seroconversion versus 55 patients with HBsAg seroconversion) were compared based on HBsAg seroconversion status. Multivariate logistic regression analysis revealed that age was independently associated with HBsAg seroconversion (odds ratio = 0.926; 95% confidence interval (CI) 0.874 to 0.981;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.